<DOC>
	<DOCNO>NCT02613221</DOCNO>
	<brief_summary>To evaluate combination panitumumab TAS-102 patient RAS wild-type metastatic colorectal cancer ( CRC ) refractory standard chemotherapy ( oxaliplatin , fluoropyrimidines , irinotecan anti-VEGF therapy ) .</brief_summary>
	<brief_title>A Phase I/II Study Safety Efficacy Panitumumab Combination With TAS-102 Patients With Colorectal Cancer</brief_title>
	<detailed_description>The purpose study evaluate combination panitumumab TAS-102 patient RAS wild-type metastatic colorectal cancer ( CRC ) refractory standard chemotherapy ( oxaliplatin , fluoropyrimidines , irinotecan anti-VEGF therapy ) . Patients judge eligible study base inclusion exclusion criterion receive panitumumab ( 6 mg/kg ) every 2 week TAS-102 ( 35 mg/m² give orally twice day 28-day ) 2-week cycle 5 day treatment follow 2-day rest period , 14-day rest period . A maximum 58 subject enrol .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>1 . Investigator subinvestigator judge candidate understand clinical trial comply protocol . 2 . Participants give write consent take part study detail explanation study prior enrollment 3 . Aged ≥20 &lt; 75 year time inform consent 4 . Participants unresectable adenocarcinoma originate large intestine ( exclude carcinoma appendix anal canal cancer ) 5 . Participants lesion ( ) evaluate . It essential evaluate tumor accord RECIST ver . 1.1 . 6 . Participants receive chemotherapy metastatic colorectal cancer refractory fail chemotherapies* include ; fluoropyrimidines , irinotecan , oxaliplatin , antivascular endothelial growth factor ( VEGF ) agent . * : Refractory fail chemotherapy defy follow ; 7 . Participants classify KRAS/NRAS wildtype** KRAS/NRAS testing* . * : KRAS/NRAS test perform use vitro diagnostic list National Health Insurance . ** : Participants mutation codon show consider wild type . KRAS : EXON2 ( codon 12 , 13 ) , EXON3 ( codon 59 , 61 ) , EXON4 ( codon 117 , 146 ) NRAS：EXON2 ( codon 12 , 13 ) , EXON3 ( codon 59 , 61 ) , EXON4 ( codon 117 , 146 ) 8 . Participants able take medication orally . 9 . Participants satisfy follow criterion major organ function test perform within 14 day prior enrollment 1 ) Neutrophil count 1.5×103/µL 2 ) Platelet count 1.0×104/µL 3 ) Hemoglobin 8.0 g/dL 4 ) Total bilirubin 1.5 mg/dL 5 ) AST 100 IU/L ( 200 IU/L liver metastasis present ) 6 ) ALT 100 IU/L ( 200 IU/L liver metastasis present ) 7 ) Serum creatinine 1.5 mg/dL 10 . ECOG performance status ( PS ) 0 1 11 . Life expectancy ≥ 3 month ( 90 day ) enrollment 1 . Has receive antiEGFR antibody ( cetuximab panitumumab ) , regorafenib , TAS102 . 2 . Has treatment radiotherapy and/or chemotherapy within 2 week ( 14 day ) prior study drug administration ( except limit field radiation order rescue pain ) . 3 . Known brain metastasis strongly suspect brain metastasis 4 . Synchronous cancer metachronous cancer diseasefree period ≥ 5 year ( exclude colorectal cancer ) exclude mucosal cancer cure possibly cure regional resection ( esophageal , stomach , cervical cancer , nonmelanoma skin cancer , bladder cancer , etc. ) . 5 . Body cavity fluid require treatment ( pleural effusion , ascites , pericardial effusion , etc . ) 6 . Participants want use contraception prevent pregnancy , woman pregnant breastfeeding , test positive pregnancy 7 . Any investigational agent receive within prior 4 week ( 28 day ) . 8 . Disease require systemic steroid treatment ( exclude topical steroid ) 9 . History obvious extensive CT finding interstitial pulmonary disease ( interstitial pneumonia , pulmonary fibrosis , etc . ) 10 . Intestinal paralysis , gastrointestinal obstruction , uncontrollable diarrhea ( incapacitate symptom despite adequate treatment . 11 . Serious drug hypersensitivity ( without allergy oxaliplatin ) 12 . Local systemic active infection require treatment , fever indicate infection 13 . NYHA class II high heart failure serious heart disease 14 . Active hepatitis B 15 . Known HIV infection 16 . Peripheral neuropathy ≥ Grade 2 CTCAE ( Japanese edition JCOG version 4.03 ) 17 . Known BRAF mutation 18 . Other participant judge investigator subinvestigator ineligible enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Metastatic colorectal cancer , Panitumumab , TAS-102</keyword>
</DOC>